Safety and efficacy of BV-ESHAP therapy for relapsed and refractory Hodgkin's lymphoma before transplantatio

Phase 2

• Conditions: Hodgkin' s lymphoma

• Registration Number: JPRN-UMIN000019361
• Lead Sponsor: Department of Hematology, Keio University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-10-16
• Study Completion: 2016-02-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

Not provided

Exclusion Criteria

AST, ALT is over 2.5 times upper limit of normal controls, or total bilirubin is over 2.0mg/dl.(exclude for abnormal due to primary disease) Creatinine is over 1.5 mg/dl. Showed severe abnormalities on echocardiograms or ultrasonic cardiography, or congestive heart failure. Have severe interstitial pneumonia, or past history of interstitial pneumonia. Allergic to etoposide, cytarabine, cisplatin, or G-CSF. HIV antibody or HBV-DNA is positive. Have severe uncontrollable disease(for example, cerebral disease, diabetes mellitus, or severe psychological diseases). Considered as inadequate for this study by study director, or members of this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
overall response rate after therapy (CR and PR on PET-CT)

Secondary Outcome Measures

Name	Time	Method
collected number of CD34 positive cells/adverse events/Overall survival/relapse-free survival